A radioimmoassay for digoxin is described which uses commercially available reagents. Two assay procedures are used, one for batch assays, and another, which needs a 5 minute incubation only, for 'stat' assays. The methods are shown to be simple, rapid, precise and inexpensive and the batch procedure compared well with the Amerlex digoxin method for 63 patient samples.
The measurement of digoxin in plasma or serum is now a well-recognised part of therapeutic drug monitoring, I and the clinical usefulness of digoxin concentrations has been established.v 3 This is particularly important where drug interactions can markedly influence the relationship of the dose to the plasma concentration, as with digoxin and arniodarone." A number of external qualityassessment schemes exist for digoxin, and perusal of method codes indicates that the majority of laboratories use commercial kits."
A general approach to simple and cheap in-house assays using commercially available reagents'" 6 was extended to digoxin assays. The intention was to produce a simple, reliable and cheap routine method, with a provision for speedy processing of samples outside normal laboratory hours. [ 125I]digoxin tracer was diluted in assay buffer to produce about 200 000 cpm/mL; antiserum was diluted in buffer so that 50-75% of total counts (10 000 cpm/tube) were bound in the zero-dose tube.
Two separate procedures were adopted, a batch procedure and a much faster 'stat' assay. In the former, 100 ILL volumes of sample, standard or control were pipetted into plastic tubes (Luckhams LP3), followed by 50 ILL of tracer and lOO ILL of antiserum. The tubes were mixed and incubated at room temperature for 20 min. Then 100 ILL of solid-phase second antibody, already at room temperature, was added, the tubes mixed, and incubation continued at room temperature for a further 20 min. One millilitre of distilled water was added to each tube and the tubes centrifuged at room temperature at 2000 g for 2-5 min. The supernatant fluid was removed by aspiration and the precipitate counted for 60 s on a multi-head gamma counter (Multigamma, LKB Ltd, Selsdon, Surrey). Percentage binding (B -NSBIB" -NSB) was calculated and the standard curve fitted to a spline function. Results of unknown specimens were calculated automatically.
In the 'stat' procedure, 100 ILL of sample, 50 ILL of tracer, 100 ILL of antiserum and 100 ILL of solid-phase second antibody were all added together and the tubes mixed and incubated at room temperature for 5 min. One millilitre of distilled water was then added, the tubes were centrifuged and the precipitates counted as described.
Patients' samples (serum or heparinised plasma) measured using the batch procedure were also measured using the Amerlex digoxin radioimmunoassay (Amersham International. Amersham, Bucks). This assay was carried out using the quantities of reagents and method specified by the manufacturer.
Digoxin concentrations are given as ng/mL; values must be multiplied by 1·28 for conversion to nmol/L. The accepted therapeutic range for digoxin in patients with normal renal function is 0·8-1·6 ng/ml.."
were lower with the batch procedure. In the 'stat' procedure, no effect of incubation times between 5 and 30 min on zero-dose binding could be demonstrated.
The cross-reactivity of both digitoxin and amiodarone were determined for this antiserum; at 50% displacement, cross-reactivity to digitoxin was 1·3%, and was much less than 1% for amiodarone. Recovery of digoxin added to plasma samples at concentrations of 0·9 and 2·25 ng/mL was always between 92 and 107%.
Comparison of results obtained by the batch procedure with results from the Amerlex radioimmunoassay for 63 patient samples is shown in Fig. 2 . The intercept (-0·03±0·03 
Results
The standard curve for the batch procedure in Fig. 1 was similar to that obtained in the 'stat' procedure; in both circumstances the nonspecific binding was about 2·5% of total counts. Mean values for three human serum control samples run in every batch and stat assay for 1 month were not significantly different (Table  1) , although inter-assay coefficients of variation ng/mL, mean ± SEM) was not significantly different from zero nor the slope (l·03±0·02) from unity; the coefficient of regression was 0·988 (P<O·01).
Discussion
Digoxin has a long elimination half-life of about 36 h in man 7 which might suggest that rapid reporting of plasma concentrations was unimportant. However, the drug is often prescribed in an elderly population where mental confusion may lead to uncertainty about dose. In addition, renal insufficiency (common in the elderly) and polypharmacy may obscure the usual relationship between dose and plasma concentration. Neither gross undertreatment nor frank digoxin toxicity are uncommon in elderly patients taking digoxin, and it is these considerations which indicate the necessity for the monitoring plasma digoxin concentrations.
For the results to be useful, assays should be available reasonably frequently, and occa-sional1y it will be necessary for 'stat' assays to be performed. The objectives for the digoxin radioimmunoassay were simple methodology, sufficient speed for a 'stat' procedure and low cost. To this end, it was important to use a [ 125 I]digoxin tracer; in addition, al1 the necessary reagents were available commercially and required no radioimmunoassay expertise other than the construction of an antibody dilution curve.
Both batch and 'stat' procedures were simple, involving only the accurate pipetting of 50 and 100 ILL volumes of sample or reagent. All the incubations were carried out at room temperature, and the most critical step was ensuring that the solid-phase separating reagent was at room temperature for use. The rate of assay failure over 12 months has been less than 0·25%.
The batch procedure was relatively rapid, with total incubation and centrifugation times of 45 min; routinely the interval between the start of an assay and the reporting of the results was little over an hour using a multi-head gamma counter with data reduction facilities. Preliminary investigations had shown that the time required for the equilibrium between anti-digoxin antiserum and tracer was as short as 5 min, and that this also held for the reaction with solid-phase second antibody. The attainment of equilibrium in similarly short times has also been observed for morphine radioimmunoassay. H Where the number of assay tubes was small, it was therefore possible to use a shortened 'stat' procedure, which gave identical results to the longer batch method (Table I ). In the shortened version. the total of incubation and centrifugation times was less than 10 min, which is ideal for emergency assays outside of normal working hours. This was not prohibited by cost, as the reagent costs were about lOp/tube; changing to the present method from a commercial radioimmunoassay kit has produced a saving of over £4000 a year with a digoxin workload of 3600 tests a year.
Previous comparisons of commercial kits have demonstrated that quite large differences in results for patients' samples can be obtained." In this study the comparison was with the Amerlex procedure, which is one of the most widely used methods for digoxin assay in the UK. The comparison was excellent, with neither the intercept nor the slope being significantly different from the line of identity (Fig. 2) . Inter-assay coefficients of variation obtained with the batch procedure were similar to those reported for commercial radioimmunoassay kits."
The procedures described here offer simple and rapid methodology with commercially available reagents, together with assay performance which matches that of commercial kit assays.
